Teva Pharmaceutical Industries Limited (TEV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEV) has a cash flow conversion efficiency ratio of -0.005x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-40.00 Million ≈ $-46.76 Million USD) by net assets (€8.23 Billion ≈ $9.62 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Teva Pharmaceutical Industries Limited fund operations to measure how many days the company can operate on defensive assets alone.
Teva Pharmaceutical Industries Limited - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Teva Pharmaceutical Industries Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Teva Pharmaceutical Industries Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Teva Pharmaceutical Industries Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
People's Insurance of China Ltd
SHG:601319
|
0.073x |
|
Trip.com Group Ltd ADR
NASDAQ:TCOM
|
0.014x |
|
JSW Steel Limited
NSE:JSWSTEEL
|
0.141x |
|
Telefonaktiebolaget LM Ericsson B ADR
NASDAQ:ERIC
|
0.075x |
|
Intact Financial Corporation
TO:IFC
|
0.020x |
|
SSE PLC ADR LS-50 1
F:SCTA
|
N/A |
|
Powszechna Kasa Oszczednosci Bank Polski SA
WAR:PKO
|
0.131x |
|
HCL Technologies Limited
NSE:HCLTECH
|
0.083x |
Annual Cash Flow Conversion Efficiency for Teva Pharmaceutical Industries Limited (2015–2025)
The table below shows the annual cash flow conversion efficiency of Teva Pharmaceutical Industries Limited from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Teva Pharmaceutical Industries Limited worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.91 Billion ≈ $9.25 Billion |
€1.65 Billion ≈ $1.93 Billion |
0.208x | -4.42% |
| 2024-12-31 | €5.72 Billion ≈ $6.69 Billion |
€1.25 Billion ≈ $1.46 Billion |
0.218x | +53.11% |
| 2023-12-31 | €8.13 Billion ≈ $9.50 Billion |
€1.16 Billion ≈ $1.35 Billion |
0.142x | -22.17% |
| 2022-12-31 | €8.69 Billion ≈ $10.16 Billion |
€1.59 Billion ≈ $1.86 Billion |
0.183x | +157.78% |
| 2021-12-31 | €11.24 Billion ≈ $13.15 Billion |
€798.00 Million ≈ $932.95 Million |
0.071x | -35.44% |
| 2020-12-31 | €11.06 Billion ≈ $12.93 Billion |
€1.22 Billion ≈ $1.42 Billion |
0.110x | +121.39% |
| 2019-12-31 | €15.06 Billion ≈ $17.61 Billion |
€748.00 Million ≈ $874.49 Million |
0.050x | -67.94% |
| 2018-12-31 | €15.79 Billion ≈ $18.46 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.155x | +30.47% |
| 2017-12-31 | €18.75 Billion ≈ $21.91 Billion |
€2.23 Billion ≈ $2.60 Billion |
0.119x | +6.78% |
| 2016-12-31 | €34.99 Billion ≈ $40.91 Billion |
€3.89 Billion ≈ $4.55 Billion |
0.111x | -39.97% |
| 2015-12-31 | €29.93 Billion ≈ $34.99 Billion |
€5.54 Billion ≈ $6.48 Billion |
0.185x | -- |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more